About Dyne Therapeutics
Dyne Therapeutics is a company based in Cambridge (United States) founded in 2017. The company has 191 employees as of December 31, 2024. Dyne Therapeutics offers products and services including DYNE-101, DYNE-251, and DYNE-302. Dyne Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 191 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dyne Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$317.42 M (USD)-34.54as on Dec 31, 2024
-
EBITDA
-$341.64 M (USD)-42.53as on Dec 31, 2024
-
Latest Funding Round
$115.7 M (USD), Post-IPO
Aug 10, 2020
-
Investors
Citadel
& 7 more
-
Employee Count
191
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Dyne Therapeutics
Dyne Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DYN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Dyne Therapeutics
Dyne Therapeutics offers a comprehensive portfolio of products and services, including DYNE-101, DYNE-251, and DYNE-302.
Targets DM1 disease to stop progression in neuromuscular patients.
Focuses on DMD disease for improved muscle function.
Addresses FSHD disease to enhance patient outcomes.
People of Dyne Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Software Development Team
13 people
Finance and Accounting
6 people
Data Analysis and Operations Team
4 people
Legal and Compliance
4 people
Human Resources and Administration
3 people
Operations Team
3 people
Product Management Team
2 people
Unlock access to complete
Funding Insights of Dyne Therapeutics
Investors in Dyne Therapeutics
Dyne Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Atlas Venture and Vida Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked |
Investor details for Dyne Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dyne Therapeutics
Investment portfolio details for Dyne Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dyne Therapeutics
Detailed financials for Dyne Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dyne Therapeutics Comparisons
Peer comparison for Dyne Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dyne Therapeutics
Dyne Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Dyne Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dyne Therapeutics
Complete news archive for Dyne Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dyne Therapeutics
Dyne Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Dyne Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
As of Dec 31, 2024, the latest employee count at Dyne Therapeutics is 191.
Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.
Dyne Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
Dyne Therapeutics offers DYNE-101, DYNE-251, and DYNE-302.
Yes, Dyne Therapeutics is publicly traded on NASDAQ under the ticker symbol DYN.
Dyne Therapeutics has 8 investors. Key investors include Citadel, Atlas Venture, Vida Ventures, Wellington, and Logos Capital.
The ticker symbol of Dyne Therapeutics is DYN on NASDAQ.